Companies: 10,795·Total market cap: $144.5T
Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.

KYMRNASDAQHealthcare● Active
$73.61
$-0.52(-0.71%)
Market Cap$6.1B
P/E Ratio
52W High$103
52W Low$36.65
Overview

Kymera Therapeutics, Inc. (KYMR) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · KYMR · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-3.58kymr eps ttm · kymr earnings per shareEarnings history
PE Ratio (TTM)kymr pe ratio ttm · kymr price to earningsPE Ratio deep dive
Revenue (TTM)$51.5Mkymr revenue ttm · kymr annual revenueFull revenue history
Dividend YieldNo Dividenddoes kymr pay dividends · kymr dividend yieldDividend history
Shares Outstanding84.4Mkymr shares outstanding · kymr floatShares outstanding history
Next EarningsAug 10, 2026Est.kymr earnings date · kymr next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$39.2M▼ 16.72% YoY
202320242025
kymera therapeutics, inc. revenue · kymr revenue 2025
FY 2025Net Income-$311.4M▼ 39.11% YoY
202320242025
kymera therapeutics, inc. net income · kymr profit 2025
FY 2025EPS$-3.69▼ 23.83% YoY
202320242025
kymr eps · kymera therapeutics, inc. earnings per share 2025
TTM:Revenue: $51.5MNet Income: -$315.1MEPS: $-3.58View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy26 analystsis kymr a buy · kymr analyst rating
Strong Buy
0
Buy
23
Hold
3
Sell
0
Strong Sell
0
12-Month Price Target
$106.00Low
$73.61Current
$120.36Avg Target63.52% upside
$138.00High
kymr price target · kymr 12 month forecast

Total: 26 · Buy rate: 88.5%

The KYMR analyst consensus is Buy, based on ratings from 26 Wall Street analysts over the past 3 months. The average 12-month price target is $120.36, representing +63.52% upside from the current price of $73.61.

Stock Performance

Full History
1D-0.75%
1W+3.66%
1M-14.52%
3M-11.87%
YTD-5.44%
1Y+56.02%
5Y+51.55%

About Kymera Therapeutics, Inc.

CEONello Mainolfi
IPO DateAug 21, 2020
Employees208
CountryUS

Kymera Therapeutics, Inc. a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body…

what is kymera therapeutics, inc. · kymr stock overview · kymera therapeutics, inc. company profile · who is kymera therapeutics, inc. ceo · kymr NASDAQ · kymera therapeutics, inc. headquarters · kymera therapeutics, inc. business segments

About Stock Overview & Key Data

Kymera Therapeutics, Inc. (KYMR) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Aug 21, 2020. As of the latest trading session, KYMR stock price is $73.61, with a market capitalization of $6.1B. The stock has returned +56.02% over the past 12 months and -5.44% year-to-date.

According to 26 Wall Street analysts, the consensus rating for Kymera Therapeutics, Inc. stock is Buy, with an average 12-month price target of $120.36. In fiscal year 2025, Kymera Therapeutics, Inc. reported revenue of $39.2M and net income of -$311.4M. For detailed data — including Kymera Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Kymera Therapeutics, Inc. (KYMR) stock price is $73.61. The stock is traded on NASDAQ under the ticker symbol KYMR. The 52-week range is $36.65 – $103.00.

KYMR stock priceKYMR quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice